Zoledronic acid with either standard or reduced dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized study.

Atahan, L.Yildiz, F.Cengiz, M.Kaplan, B.Ozkan, M.Haydaroglu, A.Sengoz, M.Korcums, A. F.Akmansu, M.Engin, K.2019-10-272019-10-2720060360-3016https://doi.org/10.1016/j.ijrobp.2006.07.980https://hdl.handle.net/11454/3890448th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and-Oncology -- NOV 05-09, 2006 -- Philadelphia, PAen10.1016/j.ijrobp.2006.07.980info:eu-repo/semantics/closedAccessZoledronic acid with either standard or reduced dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: A phase IV randomized study.Conference Object663S524S525WOS:000241221602079Q1